BR9611671A - Method for targeting dosages of drugs and therapeutic agents and other glycosaminoglycans (gags) to treat a disease or condition in a human being. - Google Patents
Method for targeting dosages of drugs and therapeutic agents and other glycosaminoglycans (gags) to treat a disease or condition in a human being.Info
- Publication number
- BR9611671A BR9611671A BR9611671-4A BR9611671A BR9611671A BR 9611671 A BR9611671 A BR 9611671A BR 9611671 A BR9611671 A BR 9611671A BR 9611671 A BR9611671 A BR 9611671A
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- liver
- disease
- human
- condition
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 10
- 229940124597 therapeutic agent Drugs 0.000 title abstract 5
- 229940079593 drug Drugs 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title abstract 2
- 229920002683 Glycosaminoglycan Polymers 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 9
- 210000004185 liver Anatomy 0.000 abstract 9
- 230000000694 effects Effects 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- 230000014759 maintenance of location Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
''MéTODO DE ALVEJAMENTO DE DOSAGENS DE MEDICAMENTOS E DE AGENTES TERAPêUTICOS E DE OUTROS GLICOSAMINOGLICANOS (GAGS) PARA TRATAR DE UMA DOENçA OU CONDIçãO EM UM SER HUMANO''. é provido um método de tratamento de uma doença ou condição em um ser humano tratável por um medicamento e/ou agente terapêutico que pode ser transportado por um agente ao local em necessidade de tratamento no corpo e cujo agente pode também transportar o medicamento e/ou agente terapêutico ao fígado (por exemplo, pela ligação do agente de transporte aos receptores do fígado), compreendendo: (a) a administração de uma quantidade efetiva não tóxica de um primeiro agente que não se liga aos receptores do local em necessidade de tratamento mas que se liga aos receptores do fígado, reduzindo com isso a atividade do fígado; e (b) a administração, depois disso, de uma quantidade efetiva não tóxica de um medicamento e/ou agente terapêutico e de uma quantidade efetiva de um segundo agente que é um agente de transporte e é um agente diferente do primeiro agente, e o qual segundo agente se liga ao local em necessidade de tratamento e seria capaz de se ligar aos locais do fígado se o fígado não tivesse sua atividade reduzida de modo que sua capacidade de ligação do fígado com o segundo agente tenha sido substancialmente reduzida pela retenção pelo fígado do primeiro agente administrado sob o sub-parágrafo (a), por exemplo, pela ligação com os receptores de limpeza do fígado.'' METHOD OF TARGETING DOSES OF MEDICINES AND THERAPEUTIC AGENTS AND OTHER GLYCOSAMINOGLICANS (GAGS) TO TREAT A DISEASE OR CONDITION IN A HUMAN BEING ''. a method of treating a disease or condition in a human being treatable by a drug and / or therapeutic agent is provided which can be transported by an agent to the location in need of treatment on the body and whose agent can also transport the drug and / or therapeutic agent to the liver (for example, by binding the carrier to the liver receptors), comprising: (a) administering an effective non-toxic amount of a first agent that does not bind to the site receptors in need of treatment but that binds to liver receptors, thereby reducing liver activity; and (b) the administration thereafter of an effective non-toxic amount of a drug and / or therapeutic agent and an effective amount of a second agent which is a carrier and is a different agent from the first agent, and the which second agent binds to the site in need of treatment and would be able to bind to sites in the liver if the liver did not have its activity reduced so that its ability to bind the liver to the second agent has been substantially reduced by liver retention of the first agent administered under sub-paragraph (a), for example, by binding to the liver cleansing receptors.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002164260A CA2164260C (en) | 1995-12-01 | 1995-12-01 | Targeting of dosages of medicines and therapeutic agents |
| CA 2173037 CA2173037A1 (en) | 1996-03-29 | 1996-03-29 | Targeting of dosages of medicines and therapeutic agents and other glycosaminoglycans (gags) |
| PCT/CA1996/000793 WO1997020564A1 (en) | 1995-12-01 | 1996-11-29 | Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9611671A true BR9611671A (en) | 1999-12-28 |
Family
ID=25678243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9611671-4A BR9611671A (en) | 1995-12-01 | 1996-11-29 | Method for targeting dosages of drugs and therapeutic agents and other glycosaminoglycans (gags) to treat a disease or condition in a human being. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0869798A1 (en) |
| JP (1) | JP2000513707A (en) |
| KR (1) | KR19990071628A (en) |
| AU (1) | AU727001B2 (en) |
| BR (1) | BR9611671A (en) |
| HU (1) | HUP9901935A3 (en) |
| IL (1) | IL124647A0 (en) |
| MX (1) | MX9804343A (en) |
| NO (1) | NO982441L (en) |
| PL (1) | PL326970A1 (en) |
| WO (1) | WO1997020564A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITPD940054A1 (en) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | SULPHATED POLYSACCHARIDES |
| NZ512676A (en) | 1999-01-13 | 2003-01-31 | Meditech Res Ltd | A composition and method for the enhancement of the efficacy of drugs |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| AUPQ879500A0 (en) | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| AU2006274509B2 (en) * | 2005-07-27 | 2012-01-19 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| BRPI0615619A2 (en) | 2005-09-07 | 2011-05-24 | Alchemia Oncology Pty Ltd | therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| AUPM714794A0 (en) * | 1994-07-29 | 1994-08-18 | International Fluid Separation Pty Limited | Separation apparatus and method |
| HUT76846A (en) * | 1994-08-30 | 1997-12-29 | Hyal Pharma Corp | Hyaluronic acid and derivatives for modulation of cellular activity |
-
1996
- 1996-11-29 BR BR9611671-4A patent/BR9611671A/en not_active Application Discontinuation
- 1996-11-29 KR KR1019980703904A patent/KR19990071628A/en not_active Ceased
- 1996-11-29 AU AU76878/96A patent/AU727001B2/en not_active Ceased
- 1996-11-29 WO PCT/CA1996/000793 patent/WO1997020564A1/en not_active Ceased
- 1996-11-29 EP EP96939774A patent/EP0869798A1/en not_active Ceased
- 1996-11-29 PL PL96326970A patent/PL326970A1/en unknown
- 1996-11-29 JP JP09520818A patent/JP2000513707A/en not_active Ceased
- 1996-11-29 HU HU9901935A patent/HUP9901935A3/en unknown
- 1996-11-29 IL IL12474796A patent/IL124647A0/en not_active IP Right Cessation
-
1998
- 1998-05-28 NO NO982441A patent/NO982441L/en unknown
- 1998-06-01 MX MX9804343A patent/MX9804343A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990071628A (en) | 1999-09-27 |
| AU727001B2 (en) | 2000-11-30 |
| AU7687896A (en) | 1997-06-27 |
| NO982441D0 (en) | 1998-05-28 |
| EP0869798A1 (en) | 1998-10-14 |
| HUP9901935A3 (en) | 2001-04-28 |
| WO1997020564A1 (en) | 1997-06-12 |
| JP2000513707A (en) | 2000-10-17 |
| IL124647A0 (en) | 1998-12-06 |
| HUP9901935A2 (en) | 1999-11-29 |
| NO982441L (en) | 1998-05-28 |
| MX9804343A (en) | 1998-09-30 |
| PL326970A1 (en) | 1998-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2203653C2 (en) | Using n-propargyl-1-aminoindane r-enantiomer, its salts and compositions comprising thereof | |
| KR950002785A (en) | Parathyroid hormone and raloxyphene to increase bone mass | |
| ES2162615T3 (en) | METHOD TO TREAT OR PREVENT TYPE 1 DIABETES THROUGH ORAL INSULIN ADMINISTRATION. | |
| BR9909277A (en) | Compounds with activity at muscarinic receptors | |
| KR930007441A (en) | medicine | |
| PT1098643E (en) | PHENYLACETILGLUTAMINE PHENYLACETYLISOGLUTAMINE AND / OR PHENYLACETATE FOR THE TREATMENT OF NEOPLASTIC DISEASES | |
| BR9916114A (en) | Use of apomorphine in the manufacture of a medicament for treating male organic erectile dysfunction | |
| DE69733089D1 (en) | Treatment of osteotarthritis by administration of poly-N-acetyl-D-glucosamine | |
| BR9807796A (en) | Processes to treat urinary incontinence, vertigo and motion sickness, and pharmaceutical composition. | |
| KR950007848A (en) | Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide | |
| MY124465A (en) | Reduction of infarct volume using citicoline | |
| BR9611671A (en) | Method for targeting dosages of drugs and therapeutic agents and other glycosaminoglycans (gags) to treat a disease or condition in a human being. | |
| BR0207866A (en) | Use of flumazenil in the preparation of a drug for the treatment of cocaine addiction | |
| BR0211855A (en) | Drug and method for treating and improving restorative sleep quality | |
| US4312865A (en) | Medication having penetration through cutaneous surfaces into articular and muscular areas | |
| MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
| BR9612355A (en) | Binding agents with hyaluronic acid receptors and their use. | |
| Cooper et al. | The analgesic efficacy of flurbiprofen compared to acetaminophen with codeine | |
| BR0208920A (en) | Single dose aromatase inhibitor for infertility treatment | |
| KR890007728A (en) | Painkiller | |
| RU94032792A (en) | Application of 5htia-antagonists for tobacco use stopping | |
| SE8804640L (en) | MEDICINAL COMPREHENSIVE CYCLOLINOPEPTIDE A | |
| SU1553132A1 (en) | Method of treating reactive postinfection arthritis | |
| Bohl et al. | A clinical trial comparing a new NSAID (droxicam) and piroxicam in spinal osteoarthritis | |
| KR900017599A (en) | Pharmaceutical composition for tumor treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/728 (2006.01), A61K 31/726 (2006.0 |